Matinas BioPharma Holdings (MTNB) Cash from Operations (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Cash from Operations of 1601000.0 for Q1 2026, up 20.23% year-over-year from 1331623.29 in Q1 2025, and down 6.1% quarter-over-quarter from 1509000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Cash from Operations (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Cash from Operations for 14 consecutive years, with 1601000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 20.23% year-over-year to 1601000.0; the TTM figure through Mar 2026 stood at 6605000.0 (up 45.52% YoY), while the FY2025 annual figure was 7011000.0, up 55.86% from the prior year.
- Cash from Operations fell to 1601000.0 in Q1 2026 per MTNB's latest filing, from 1509000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1474000.0 in Q3 2025 and bottomed at 5769000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 3466529.41 across 5 years, with a median of 3510000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 493.42% — and 2025, when it surged 65.21%.
- Matinas BioPharma Holdings' Cash from Operations stood at 4299000.0 in 2022, then retreated by 6.51% to 4579000.0 in 2023, then climbed by 23.35% to 3510000.0 in 2024, then jumped by 57.01% to 1509000.0 in 2025, then dropped by 6.1% to 1601000.0 in 2026.
- Business Quant data shows MTNB's Cash from Operations at 1601000.0 in Q1 2026, 1509000.0 in Q4 2025, and 1474000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | -1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.84 Mn |
| Jun 30, 2026 | -1.84 Mn |
| Mar 31, 2026 | -1.60 Mn |
| Mar 31, 2026 | -1.60 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Jun 30, 2025 | -2.02 Mn |
| Jun 30, 2025 | -2.02 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Sep 30, 2024 | -3.50 Mn |
| Sep 30, 2024 | -3.50 Mn |
| Jun 30, 2024 | -3.11 Mn |
| Jun 30, 2024 | -3.11 Mn |
| Mar 31, 2024 | -5.77 Mn |
| Mar 31, 2024 | -5.77 Mn |